Randomized, double-blind, placebo-controlled trial of meriva (r) as a candidate chemoprevention agent for gastric carcinogenesis
Ended Awarded Last action
- Contract number
- HHSN26100010
- Awardee
-
Mayo Clinic UEI Y2K4F9RPRRG7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $748,354
Award facts
- Opportunity
-
- N01CN0501469 Solicitation number
- Contract value 100% obligated
- $748,353.67 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Rochester, MN 55905, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $11,000 | |
| Funding Only Action | $25,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Change Order | $48,976 | |
| Supplemental Agreement for work within scope | $41,160 | |
| Supplemental Agreement for work within scope | $26,790 | |
| Supplemental Agreement for work within scope | $13,250 | |
| Other Administrative Action | $24,042 | |
| Other Administrative Action | $19,999 | |
| Original award | $538,137 |
Show all 11
About this award
This is a federal contract award from the National Cancer Institute (NCI), a component of the National Institutes of Health, to Mayo Clinic. The contract, valued at $748,353.67, is for a randomized, double-blind, placebo-controlled trial of the compound Meriva as a potential chemopreventive agent for gastric carcinogenesis. This work is being conducted under the NCI's Clinical Prevention Agent Development Program, which focuses on early-phase clinical research. The contract does not have a set-aside designation.
Mayo Clinic has subcontracted with the University of Puerto Rico Medical Sciences Campus (UPR-MSC) to enroll subjects and conduct the clinical trial. UPR-MSC is a minority-serving, Hispanic-serving, and educational institution that has received various federal contracts and grants, including work with the Department of the Navy. This contract supports the NCI's efforts to develop new interventions for cancer prevention and treatment.
Quick answers
Who was awarded contract HHSN26100010?
HHSN26100010 was awarded to Mayo Clinic by National Cancer Institute (National Institutes of Health) on August 1, 2016.
How much is contract HHSN26100010 worth?
The government has obligated $748,354 on HHSN26100010.
Is contract HHSN26100010 an order under another contract?
Yes. HHSN26100010 is a delivery order under HHSN261201200042I, an indefinite delivery contract.
Was contract HHSN26100010 competed?
The extent of competition for HHSN26100010 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award